Posted inResearch
Owkin, Servier ink oncology R&D deal to guide discovery and trial design
AI drug discovery company Owkin has signed a pact with French drugmaker Servier to license Owkin’s AI scientist K Pro…
Posted inBiotechnology
MT2M: Cost-Driven Strategy for Cyber Defense Under Changing Constraints
Cybersecurity researchers have unveiled a new game-theoretic framework that promises to make one of the field’s most promising proactive defense…
Posted inBiotechnology
Mobile network data reveals Bologna’s mobility patterns through spatiotemporal event analysis
Mobile phone networks have quietly become one of the most powerful scientific instruments for understanding how cities breathe, and a…
Posted inBiotechnology
MSENet: Lightweight Deep Learning for Inertial Localization and Wireless Sensing
Every time a delivery robot loses its way in a warehouse corridor, or a fitness tracker reports a distance that…
Posted inBiotechnology
New multi-scale fuzzy method enables unsupervised attribute reduction
Every dataset that arrives at a machine learning pipeline carries a burden: columns of measurements, sensor readings, pixels or clinical…
Posted inBiotechnology
Beyond clinical endpoints: Rethinking ALS drug development through disease biology
After decades of hard-won progress, ALS drug development is entering a new era, building on established efficacy measures like survival…
Posted inBiotechnology
The future of RAS inhibitors
Revolution Medicines recently made history with the approval of its RAS inhibitor Rasonque for advanced pancreatic cancer. But behind RevMed…
Posted inBiotechnology
FDA delays approval decision for Exelixis’ tyrosine kinase inhibitor in colorectal cancer
The FDA has delayed its approval decision for Exelixis’ oral kinase inhibitor in combination with Roche’s Tecentriq for the treatment…
Posted inBiotechnology
BioNTech sets survival standard in hard-to-treat cancer ahead of pivotal readout
BioNTech has linked gotistobart to median overall survival of 18.5 months in relapsed lung cancer patients, adding to evidence that…
Posted inBiotechnology
m6A-Regulated Histone Lactylation by Fibronectin 1 Drives GIST Progression
Scientists have uncovered a previously unrecognized mechanism that drives the malignant progression of gastrointestinal stromal tumors, one of the most…